1030 Massachusetts Avenue
Tel: (781) 806-6245
About Obsidian Therapeutics
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients for the treatment of cancer and other diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
Located in the heart of Cambridge, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.
41 articles with Obsidian Therapeutics
Obsidian Therapeutics , Inc. , a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the i
Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Robert Ross , M.D., to its Board of Directors. Dr. Ross currently s
Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19
Implementation has enabled Obsidian to remain on track to meet development targets, while maintaining a safe working environment for all employees
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Anders Götzsche to its Board of Directors
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, announced the formation of its Scientific Advisory Board (SAB).
Additions support Obsidian's active program development, operational build-out and ongoing regulatory discussions
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Erin Boyer as Vice President, Human Resources
What if you could more precisely control CAR-T cells using FDA-approved small molecules to enhance their activity against solid tumors? That’s exactly what Obsidian Therapeutics is aiming to do.
7/26/2019Biotech and pharma companies bolster their executive leadership and boards of directors with this week's appointments.
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced executive management appointments that organizationally support the Company's long-term strategy.
4/19/2019Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.
Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer
Experienced CEO brings expertise in product development, cell and gene therapies, and public biotechnology companies as Obsidian positions itself for future growth
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings
Companies enter into multi-year strategic collaboration with Celgene receiving exclusive options to license cell therapies that utilize Obsidian’s Destabilizing Domain technology to modulate IL12 and CD40L activity
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.
Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Obsidian Therapeutics to provide semi-mechanistic models and analysis services.
Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs
Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced the presentation of preclinical data demonstrating fine-tuned regulation of cytokine production and CAR-T function using Destabilizing Domains (DDs) paired with FDA-approved small molecule drugs.
Obsidian to Present Data on Regulated Cytokine Programs at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting
Obsidian Therapeutics, Inc. announced that two abstracts highlighting preclinical data on the use of its technology for regulation of immunocytokines have been selected for presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 16-19, 2018, in Chicago, IL.
Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions
Data show ability of destabilizing domain technology platform to regulate expression of secreted and membrane-bound proteins in cell therapies
Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting
Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced that an abstract highlighting preclinical data on its technology and therapeutic applications has been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.